Here we provide a selection of scientific publications related to IOZK immunotherapy. You can use the filters to make a selection according to tumor types and methods, or enter search terms.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-01-06 / BMC Cancer 2010 Jan;10:5https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-01-06 / BMC Cancer 2010 Jan;10:52010-01-06 00:00:002019-02-15 08:43:59Tocotrienols are good adjuvants for developing cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-01-01 / Int J Hyperthermia 2010;26(2):118-26https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-01-01 / Int J Hyperthermia 2010;26(2):118-262010-01-01 00:00:002010-01-01 00:00:00Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-01-01 / J. Virol. 2010 Jan;84(1):639-46https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-01-01 / J. Virol. 2010 Jan;84(1):639-462010-01-01 00:00:002010-01-01 00:00:00The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-01-01 / Int J Hyperthermia 2010;26(2):108-17https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-01-01 / Int J Hyperthermia 2010;26(2):108-172010-01-01 00:00:002019-02-15 08:39:21Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-01-01 / Hum. Immunol. 2010 Jan;71(1):67-73https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-01-01 / Hum. Immunol. 2010 Jan;71(1):67-732010-01-01 00:00:002019-02-15 08:44:09Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):95-109https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):95-1092010-01-01 00:00:002019-02-15 08:47:25Clinical applications of a peptide-based vaccine for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-01-01 / Curr. Med. Chem. 2010;17(27):3045-57https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-01-01 / Curr. Med. Chem. 2010;17(27):3045-572010-01-01 00:00:002019-02-15 09:17:27Biological rationales and clinical applications of temperature controlled hyperthermia–implications for multimodal cancer treatments
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-01-01 / Neoplasma 2010;57(5):455-64https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-01-01 / Neoplasma 2010;57(5):455-642010-01-01 00:00:002019-02-15 08:50:55Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-01-01 / Int J Hyperthermia 2010;26(7):612-7https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-01-01 / Int J Hyperthermia 2010;26(7):612-72010-01-01 00:00:002010-01-01 00:00:00Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002009-12-24 / J. Neurooncol. 2010 Jul;98(3):395-405https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2009-12-24 / J. Neurooncol. 2010 Jul;98(3):395-4052009-12-24 00:00:002009-12-24 00:00:00Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002009-12-01 / Cancer Treat. Rev. 2010 Apr;36(2):131-41https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2009-12-01 / Cancer Treat. Rev. 2010 Apr;36(2):131-412009-12-01 00:00:002019-02-15 08:53:00The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Tocotrienols are good adjuvants for developing cancer vaccines
Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study
The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum
Tumor antigen presentation by dendritic cells
Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy
Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines
Personalized dendritic cell-based tumor immunotherapy
Dendritic cell vaccines for brain tumors
Clinical applications of a peptide-based vaccine for glioblastoma
Monitoring immune responses after glioma vaccine immunotherapy
Biological rationales and clinical applications of temperature controlled hyperthermia–implications for multimodal cancer treatments
Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies
Heat shock proteins in glioblastomas
Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data
Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results
Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer
Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification